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Abstract: Idiopathic dilated cardiomyopathy (IDC) is the most common form of non-ischemic chronic
heart failure. Despite the higher prevalence of IDC in African Americans, the genetics of IDC
have been relatively understudied in this ethnic group. We performed a genome-wide association
study to identify susceptibility genes for IDC in African Americans recruited from five sites in
the U.S. (662 unrelated cases and 1167 controls). The heritability of IDC was calculated to be 33%
(95% confidence interval: 19–47%; p = 6.4 × 10−7). We detected association of a variant in a novel
intronic locus in the CACNB4 gene meeting genome-wide levels of significance (p = 4.1 × 10−8).
The CACNB4 gene encodes a calcium channel subunit expressed in the heart that is important for
cardiac muscle contraction. This variant has not previously been associated with IDC in any racial
group. Pathway analysis, based on the 1000 genes most strongly associated with IDC, showed an
enrichment for genes related to calcium signaling, growth factor signaling, neuronal/neuromuscular
signaling, and various types of cellular level signaling, including gap junction and cAMP signaling.
Our results suggest a novel locus for IDC in African Americans and provide additional insights into
the genetic architecture and etiology.
Keywords: idiopathic dilated cardiomyopathy; GWAS; CACNB4; calcium channel; African American;
heart failure
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1. Introduction
Annually, an estimated 915,000 new cases of heart failure are diagnosed, and 65,000 deaths are
attributed to the syndrome [1]. Nearly half of these cases are not due to ischemic heart disease [2].
Of these non-ischemic cardiomyopathies, idiopathic dilated cardiomyopathy (IDC) is one of the most
well characterized clinical entities and is the subject of the current work.
At least 30% of patients with IDC have an affected family member [3–5]. However, the etiology of
a significant number of IDC cases has yet to be defined, even after extensive genetic screening. Varying
clinical features of cardiomyopathy support a complex etiology even when monogenic mutations
are involved. For example, it is known that the same clinical phenotype can be caused by different
gene mutations, and conversely, mutations in the same gene can cause different clinical subsets of
cardiomyopathy in different individuals [6]. These observations suggest that genetic, environmental,
or other non-genetic modifiers could interact with myopathic-predisposing mutations to influence the
risk of development and prognosis.
A notable feature of IDC is its higher prevalence in African Americans compared as to European
Caucasians (relative odds = 2.6 with 95% confidence interval (CI) 1.6–4.3) [7,8]. For example,
African American children (<18 years old) have a higher annual incidence of dilated cardiomyopathy
than Caucasian children (0.98 versus 0.46 cases per 100,000) [9]. Whether African Americans with
IDC also experience worse outcomes compared to European Caucasians has not been adequately
studied [10], although numerous studies have reported increased mortality from heart failure in
African Americans [11–13].
It has been reported that African American athletes exhibit a greater magnitude of left ventricular
hypertrophy (LVH) in response to intense physical exercise than white athletes, suggesting potential
biological differences in cardiac adaptation between African Americans and Caucasians [14]. However,
despite the higher burden of IDC in African Americans, the three genome wide association studies
(GWASs) of primary cardiomyopathy currently reported in the National Human Genome Research
Institute (NHGRI) GWAS catalog (2 studies on IDC, 1 study on hypertrophic cardiomyopathy) are all
based on populations with European ancestry [15]. In contrast, our current study is based exclusively
in subjects with self-reported African American ancestry. Focusing on African Americans offers
two potential advantages. First, the distinctive genetic architecture of populations with African
ancestry may provide opportunities to fine map causative genetic variants and to generalize findings
obtained from European GWASs [16]. Second, studying IDC in African Americans provides potential
opportunities to understand the ethnic differences in this disease and its progression, which may
provide insights into prevention and treatment strategies. Here we report the findings from the first
African American IDC GWAS, identifying a novel variant in a calcium voltage-gated channel with
genome-wide significance, and pathway enrichment of a network of proteins with near GWAS-level
significance both known and not known to be related to cardiomyopathy, consistent with a unique
African risk profile for IDC.
2. Materials and Methods
2.1. Subjects
The Genetics of African American Heart Failure (GAAHF) consortium recruited 775 IDC cases
from five sites in the U.S. (Supplementary Table S1). Local institutional review board (IRBs) from
individual sites approved this study protocol, and informed consent was obtained from all participants.
All subjects self-identified as being African American and ranged in age from 26 to 85 years. Subjects
received a medical history interview, physical examination, routine laboratory tests, electrocardiogram,
and echocardiogram. In some cases, coronary angiogram, a computed tomography (CT), or magnetic
resonance imaging (MRI) was performed when cardiac ischemia was suspected. All subjects had
ejection fractions (EF) ≤ 40%, left ventricular end diastolic dimensions (LVEDD) ≥ 5.6 cm, and
New York Heart Association (NYHA) class III–IV symptoms. Ninety percent of patients were receiving
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β-blockers and/or angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists.
Those with a family member within three generations having medical history of heart failure were
considered to have familial cardiomyopathy and were excluded.
As controls for this study, we utilized 1167 self-identified African American participants from
the Multiethnic Study of Atherosclerosis (MESA), who had previously undergone genome-wide
genotyping with the same array (i.e., the Affymetrix Genome-Wide Human SNP Assay 6.0 from
Affymetrix, Inc., based in Santa Clara, CA, USA) at the Affymetrix Research Services Laboratory
and genotype calling based on the Affymetrix Birdseed software. MESA data were obtained from
the database of Genotypes and Phenotypes (dbGAP) (Accession: phs000209.v13.p3). Using publicly
available controls is an efficient and robust strategy for conducting GWASs provided that appropriate
quality control procedures are followed to ensure comparability of genetic data between cases and
the public controls and the control of potential population structure differences between case and
public controls [17,18]. We and others have successfully used this strategy [19–21]. MESA, conducted
across six sites in USA, is a population-based study of cardiovascular disease in asymptomatic men
and women aged 45–84 years old without known cardiovascular diseases, including heart failure,
at enrollment.
2.2. Genotyping and Data Quality Control Analysis
DNA from cardiomyopathy cases was genotyped in the Genomics Core of the University of
Maryland using the Affymetrix Genome-Wide Human SNP Assay 6.0 (1 million SNPs). Genotypes
were called using the Affymetrix Birdseed software.
After excluding monomorphic SNPs, there were 908,343 SNPs genotyped among cases and
909,622 SNPs genotyped among controls. Quality control and filtering were performed at the sample
and SNP level (workflow chart: Supplementary Figure S1). Samples were excluded if they had
high missing genotyping call rates (>1.5%), excessive heterozygosity, discordant sex determination
between genotyped data and phenotypic data, or relatedness with other study subjects identified by
the Identity-by-descent calculation in PLINK (Pi-hat > 0.125 for relatedness). A total of 662 cases and
1138 controls were retained for analysis.
For genotype level quality control, SNPs were excluded for any of the following: high missing call
rate (>1%), differential missingness between cases and controls (p < 1 × 10−3), or HWE p < 1 × 10−3 in
controls, duplication, or ambiguous genomic annotation. Our analysis focused on autosomes only.
These filtering criteria resulted in the retention of 685,400 SNPs for an initial GWAS with only directly
genotyped data. Based on this initial GWAS, we additionally excluded any SNP that showed evidence
for association at p < 1 × 10−4 but for which there was no evidence of association (p < 1 × 10−3) for
SNPs in high LD (R2 > 0.5) with the index SNP. We further compared minor allele frequency (MAF)
differences between our IDC samples and two existing African American genome-wide genotype
datasets: (1) the non-stroke samples from the Genetics of Early Onset Stroke (GEOS) study [22];
and (2) the Hapmap ASW samples. SNPs were excluded if the difference in MAF was >10%.
2.3. Principal Component Analysis
Principal component (PC) analysis was conducted using EIGENSOFT (5.0.2) [23] to account for
population structure differences between case and control samples after LD pruning (window size
100 bp, sliding window size of 5 bp, and LD threshold r2 = 0.2) (Supplementary Figure S2). The genetic
variance accounted for by each PC is plotted in Supplementary Figure S3. Logistic regression analysis,
controlling for age and gender, showed that PC1, PC9, and PC10 were significantly correlated with
disease status (p < 5.0 × 10−2). Therefore, the first 10 PCs were included as covariates for final GWA
analysis. We also merged our genotype data with the Hapmap 3 reference genome data and performed
PC analysis to verify the genetic ancestry of our samples. The results are consistent with self-reported
African American ancestry for our samples. As expected, the genetic ancestry profiles of our samples
lie between European Caucasian (CEU) and Yoruba from West Africa (YRI) (Supplementary Figure S4).
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2.4. Heritability Analysis
The heritability of IDC was estimated using the Genome-wide Complex Trait Analysis (GCTA)
tool [24]. This approach defines heritability as the proportion of phenotypic variance explained by
the full genome-wide array of SNPs. GCTA estimates the phenotype variance explained by SNPs by
fitting all the SNPs simultaneously in the model as random effects in a mixed linear model [25]. Age,
gender, and 10 PCs accounting for population structure were included as covariates in these analyses.
2.5. Imputation
Following quality control of the case and control genotypes, genotypes at additional loci were
imputed jointly based on the 1000-genome phase 1 reference panel (integrated_phase1_v3.20101123) [26].
Sex chromosomes were excluded before imputation. Imputation was based on 685,386 SNPs. Pre-phasing
was conducted in SHAPEIT2 [27] and imputation was performed using IMPUTE2 following standard
procedure [28]. Imputation resulted in generation of 27,494,467 SNPs. The imputation quality was assessed
by the imputation quality score “info” for imputed SNPs. An info score of one indicates that there is
no uncertainty for the imputed genotypes, while an info score of zero indicates a complete guess solely
based on allele frequency in the population. The quality of imputation was very high with estimated ‘info”
scores of 0.9–1 for most imputed SNPs (Supplementary Figure S5). Consistent with standard practices, we
excluded imputed SNPs with info scores <0.30. As a second metric of imputation quality, we estimated
concordance between imputed-back genotypes and original genotypes for directly genotyped SNPs. Also
reflecting high quality imputation, we observed a concordance of 90–100% for most directly genotyped
SNPs (Supplementary Figure S5).
2.6. GWAS Association Analysis and Post GWAS Quality Control
The genetic association analyses were carried out under an additive genetic model using logistic
regression with the SNPTEST software [29]. All analyses were adjusted for age, sex, and the first
10 PCs. SNPs were removed from analysis if they had an imputation quality score “info”<0.3, HWE
p < 1 × 10−6, or MAF < 1%.
2.7. Pathway Analysis
We assigned SNPs to nearest genes based on their genomic locations. Intragenic SNPs that were
located within more than one gene were not assigned a nearest gene. Intergenic SNPs were assigned
to the nearest gene if the distance was less than 40 kb. The top 1000 genes were then subjected to
pathway enrichment analysis in two complementary databases: the Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways in the Database for Annotation, Visualization and Integrated Discovery




The characteristics of participants are summarized in Supplementary Table S1. Heritability
analysis, based on directly genotyped autosomal single nucleotide polymorphisms (SNPs)
and assuming 0.04% disease prevalence, revealed that genomic variation accounted for 33%
(95% confidence interval 19–47%, p = 6.4 × 10−7) of susceptibility to IDC after accounting for age,
gender, and population structure [24]. Additional analyses revealed that most of the genetic variance
in IDC was attributable to markers on chromosomes 1, 2, 3 and 7 (Supplementary Figure S6).
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3.2. Genome-Wide Single Variant Association Analysis
The GWAS results, excluding SNPs or short indels with imputation quality measure “info” <0.3,
Hardy–Weinberg equilibrium (HWE) p < 1.0 × 10−6, or minor allele frequencies (MAFs) <1%, are
shown as a Manhattan plot in Figure 1A. Eleven SNPs showed an association with p < 1.0 × 10−6
(Table 1, Supplementary Table S2), including one cluster on chromosome 2q reaching genome-wide
statistical significance (peak variant: rs150793926; odds ratio (OR) = 0.49; p = 4.1 × 10-8). Rs150793926
is an intronic genetic variant in CACBN4, a gene encoding a subunit of a voltage-dependent calcium
channel (Figure 1B). A SNP at a second locus also achieved genome-wide significance (rs1846594
on chromosome 3), but nearby SNPs in linkage disequilibrium (LD) with rs1846594 did not show
supporting associations with IDC; thus, this SNP did not meet our standard for further follow-up.
The lambda for the genome-wide association results was 0.99 after post-GWAS quality filtering,
showing no evidence for genomic inflation (Supplementary Figure S7).
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Figure 1. (A) Manhattan plots of the genome-wide association results based on imputed data. The x-
axis shows the chromosome number, while y-axis shows the −log (p). A post genome-wide association 
study (GWAS) filter was applied including imputation quality measure “info” >0.3, Hardy–Weinberg 
equilibrium (HWE) p > 1.0 × 10−6, minor allele frequencies (MAFs) >1%; (B) Regional association plot 
with linkage disequilibrium (LD) structure for the novel CACNB4 loci. Genomic coordinates are 
shown on the x-axis, and –log (p) is shown on the y-axis to the left. The index genetic variant is shown 
in purple. The r2 values of the remaining genetic variants with the index variant are color-coded as 
indicated by the color bar to the upper right. The genes in this region are indicated at the bottom.  
Figure 1. (A) Manhattan plots of the genome-wide association results based on imputed data. The x-axis
shows the chromosome number, while y-axis shows the −log (p). A post genome-wide association
study (GWAS) filter was applied including imputation quality measure “info” >0.3, Hardy–Weinberg
equilibrium (HWE) p > 1.0 × 10−6, minor all le frequencies (MAFs) >1%; (B) Regi nal association
plot with linkage disequilibrium (LD) structure for the novel CACNB4 loci. G nomic coordinates are
shown on the x-axis, and –log (p) is show on the y- x s to the left. The index geneti va iant is shown
in purple. The r2 values of the remaining genetic variants with the index variant are color-coded as
indicated by the color bar to the upper right. The genes in this region are indicated at the bottom.
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To assess whether any additional genetic variants at the CACNB4 locus were independently
associated with cardiomyopathy, we performed a conditional analysis. After including the top variant
rs150793926 in this locus as a covariate, no other association signal in this region was observed
(Supplementary Figure S8).
Table 1. Top genome-wide association hits at p < 1.0 × 10−6.









rs150793926 152781063 GTA G 0.04 0.07 0.49 4.10 × 10−8
8 2 rs113760736 152800750 C T 0.03 0.07 0.50 1.50 × 10−7
rs12623883 152790117 A G 0.03 0.06 0.50 2.45 × 10−7
(intronic)





1 7 rs74676849 11889492 G A 0.1 0.05 2.03 6.80 × 10−7
SNPs: single nucleotide polymorphisms or short indels; CHR: chromosome; OR: odds ratio.
We also tested whether five previously reported GWAS signals that have been associated with
IDC in Caucasians were also associated with IDC in African Americans in our study [31–33]. There
was no evidence for an association with IDC for four of these five SNPs (OR = 0.82–1.44, p > 0.01)
(Supplementary Table S3); however, we did detect a potential association with the fifth SNP, rs1739843,
(p = 4.8 × 10−3). For this SNP, we observed nearly the same effect size in African Americans as was
previously reported in Caucasians [32]: OR for the C allele 1.33 (1.14–1.55, 95% CI) in our study vs. 1.39
(1.54–1.28, 95% CI) previously. Rs1739843 is located in an intronic region of HSPB7.
3.3. Pathway Analysis Based on Genome-Wide Single Variant Association Analysis
To provide a systems view of the genetic contribution to IDC, we performed a pathway analysis
of the top 1000 genes tagged by our top 3886 SNPs/indels from the GWAS results. Pathway analysis
using the Ingenuity database revealed an enrichment of associations for SNPs located in/near genes
with known cardiomyopathy-related pathways such as hypertrophy, nuclear factor of activated
T cells (NFAT) cardiac signaling, calcium signaling, gap junction signals, and cAMP signaling being
over-represented (False Discovery Rate, i.e. FDR, corrected p < 0.1) (Table 2). There was also an
enrichment for genes related to neuronal/neuromuscular synaptic signaling. We also performed Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway analysis using the DAVID tool. Consistently,
we found that genes known to be related to primary cardiomyopathy, including hypertrophic
cardiomyopathy (HCM) and IDC, were significantly enriched (KEGG pathway p = 0.004–0.06) in
our GWAS signals (Supplementary Table S4). Figure 2 shows the dilated cardiomyopathy pathway
from the KEGG pathway database [34] overlaid with genes reported in the literature to have deleterious
mutations associated with IDC (depicted in red font) and genes associated with IDC based on GWA
analysis of our dataset (depicted in blue font). Note that MYH7 and SGCD, which are modestly, albeit
not significantly, associated with IDC in our current GWAS, have mutations reported in IDC cases.
The central role of voltage-gated L-type calcium channels in regulating intracellular Ca2+ is shown.
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Table 2. Canonical pathway analysis on the top 1000 genomic loci associated with idiopathic dilated
cardiomyopathy (IDC) using the Ingenuity database. Pathways with enrichment p < 0.1 after corrected
for multiple testing are shown here, and are grouped by tissue systems.
Classification CanonicalPathways $ Rank p-Value
Corrected
p-Value * Genes in the Pathway That Are Associated with IDC
Cardiovascular
system
Role of NFAT in
cardiac
hypertrophy
1 4.3 × 10−5 0.01
GNAI1, PLCB1, CAMK2B, SRC, CALM1, PIK3R4, MRAS,
CAMK1D, PPP3CC, IGF1, PLCG2, IGF1R, CAMK2G,
ADCY2, CAMK1G, PLCL1, ADCY8, MEF2A, ADCY9
Cellular effects of
sildenafil (Viagra) 6 3.4 × 10
−4 0.02
PLCB1, MYH7, CALM1, PRKG2, PRKG1, PLCG2,





17 4.4 × 10−3 0.10
GNAI1, PLCB1, CALM1, PIK3R4, MRAS, ADRA1D,
PPP3CC, IGF1, PLCG2, IGF1R, CACNA1C, ADCY2,
ADRA2A, PLCL1, ADCY8, MEF2A, ADCY9
Cellular signals cAMP-mediatedsignaling 2 7.8 × 10
−5 0.01
GNAI1, CAMK2B, SRC, CALM1, CHRM3, CAMK1D,
PPP3CC, PDE8A, CAMK2G, GRM7, ADCY2, PDE3A,
CAMK1G, ADRA2A, OPRM1, ADCY8, AKAP6, ADCY9,
AKAP1, HTR4, XCR1
Chemokine
signaling 5 3.0 × 10
−4 0.02 GNAI1, PLCB1, CAMK2B, SRC, CALM1, MRAS,CAMK2G, CAMK1D, CAMK1G, PLCG2
Gap junction
signaling 8 7.2 × 10
−4 0.03
GNAI1, PLCB1, SRC, PIK3R4, MRAS, PRKG2, PRKG1,
PPP3CC, PLCG2, TUBB2B, ADCY2, ACTA1, PLCL1,
ADCY8, ADCY9
RhoA signaling 11 2.0 × 10−3 0.07
IGF1R, PLXNA1, DLC1, SEPT9, ARHGAP1, ANLN,
CDC42EP3, ACTA1, ARHGAP12, RHPN2, IGF1,
RAPGEF2
RhoGDI signaling 12 2.2 × 10−3 0.07
GNAI1, CDH13, CDH2, ARHGEF3, SRC, CDH12, MRAS,
CDH4, ARHGAP1, WASL, DLC1, CDH10, ACTA1, CDH8,
ARHGAP12
Calcium signaling 13 2.9 × 10−3 0.07
CAMK2B, TP63, MYH7, CALM1, CAMK1D, PPP3CC,
NFATC3, GRIK1, CAMK2G, CAMK1G, CAMKK2, ACTA1,
GRIN3A, MEF2A, CHRNA9
Protein kinase A
signaling 14 2.9 × 10
−3 0.07
CAMK2B, GNAI1, CALM1, PPP3CC, DCC, PDE3A,
ADCY2, ADCY8, PLCL1, AKAP6, PTPRS, AKAP1,
PLCB1, PTPRM, CDC25A, PTPRT, DUSP22, PLCG2,





15 3.0 × 10−3 0.07
GNAI1, PLCB1, CALM1, PRKG2, PRKG1, PPP3CC,
PLCG2, CACNA1C, ADCY2, CAMKK2, GRIN3A, ADCY8,
PLCL1, ADCY9
G-protein coupled
receptor signaling 16 3.6 × 10
−3 0.09
GNAI1, PLCB1, CAMK2B, SRC, PIK3R4, MRAS, CHRM3,
ADRA1D, PDE8A, CAMK2G, GRM7, ADCY2, PDE3A,







3 8.9 × 10−5 0.01
PLCB1, CAMK2B, SRC, TACR1, PIK3R4, CAMK1D,
PLCG2, CAMK2G, GRM7, CAMK1G, GRIN3A, KCNQ3,
PLCL1
Glioma signaling 4 2.2 × 10−4 0.02 IGF1R, CAMK2B, CALM1, MRAS, PIK3R4, CAMK2G,CAMK1D, CAMK1G, E2F3, IGF1, IGF2R, PLCG2
Netrin signaling 7 5.4 × 10−4 0.03 NFATC3, UNC5C, ABLIM3, NCK2, PRKG1, DCC,PPP3CC
Synaptic long-term
potentiation 9 1.7 × 10
−3 0.07 PLCB1, CAMK2B, CALM1, MRAS, CAMK2G, GRM7,CACNA1C, PPP3CC, PLCL1, ADCY8, GRIN3A, PLCG2
CREB signaling in





* Benjamini–Hochberg false discovery rate corrected p. $ Abbreviations in the pathway names: NFAT, nuclear
factor of activated T cells; RhoGDI, Rho GDP-dissociation inhibitor; DARPP32, Dopamine- and cAMP-regulated
phosphoprotein, Mr 32 kDa; CREB, cAMP-responsive element binding protein.
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3.4. Gene-Based Association Analysis
We also performed gene-based association analyses using two complementary approaches. First,
we performed a set-based aggregation analysis in which we aggregated SNPs based on a gene
boundary (±50 kb window) using the fastBAT method, which derives the association p-value for
a set of SNPs from an approximated distribution of the sum of chi-squared statistics [35]. Second,
we performed an eQTL-based analysis using PrediXcan [36]. PrediXcan predicts the genetically
determined transcriptome using an eQTL database specific for cardiac ventricle tissue, and correlates
the predicted gene expressio with phenoty es. No gene reached genome-wide significa ce. The most
strongly associated gene was CSPG5 (p = 6.72 × 10−5) for fastBAT nalysis (Supplementary Table S5)
and PRMT7 (p = 1.3 × 10−4) for Pr diXc analysis (Supplementary Table S6). CACNB4 was not
significantly associated with IDC in either analysis (p > 0.05).
4. Discussion
To our knowledge, only three GWAS of IDC have been previously publ shed and none in luded
African Americans [31–33]. Our analysis indicated that common genetic variations present in
African American populations account for 33% of the risk for IDC. We identified a novel intronic
locus within CACNB4 (the voltage-dependent calcium channel beta 4 subunit, also known as the
dihydropyridine-sensitive L-type calcium channel β-4 subunit) associated with the risk of IDC with
genome-wide significance (p = 4.1 × 10−8). CACNB4 is expressed in multiple human tissues including
myocytes and neuronal cells (see genecards.org), as well as the developing hearts of zebrafish [37],
rodents [38], and canines [39]. L-type calcium channels consist of a complex of α1, α2/δ, β, and γ
subunits at a 1:1:1:1 ratio. While the α1 subunit is the main component containing the channel pore,
β subunits are critical in trafficking the channels to the plasma membrane, increasing peak calcium
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current, shifting the voltage dependencies of activation and inactivation, and regulating channel gating
through interaction with protein kinases or G proteins [40]. The mammalian β subunit of this calcium
channel has four subfamilies (β1–β4), each encoded by different genes (CACNB1–CACNB4) with each
gene having splicing variants. Thus, CACNB4 plays an important role in regulating calcium signaling,
which in turn may help regulate cardiac muscle contraction. This protein is reported to interact with
mutations of sarcomere-related genes in cardiomyopathy according to a canonical KEGG pathway
database as shown in Figure 3 [41]. More direct evidence supporting the association of CACNB4
and other ion-channel genes with IDC comes from gene expression analysis of human ventricular
samples from patients with IDC: from 548 ion channel-related genes, 26 genes including CACNB4 were
identified as differentially regulated in the cardiac tissues with IDC [42].
The genome-wide significance of the association between IDC and variation of the L-type calcium
channel has additional biological plausibility based on the results of some clinical trials with calcium
channel antagonists (blockers), particularly when pooled for meta-analysis [43,44]. In patients treated
for hypertension, these studies have shown that those treated with calcium channel blockers had an
increased risk of developing heart failure compared to those receiving β-blockers, thiazide diuretics,
or angiotensin-converting enzyme inhibitors. It is also noteworthy that some studies have shown an
increased antihypertensive response to calcium channel blockers in African Americans compared to
Caucasians [45].
There are eight genetic variants in the intronic region of the CACNB4 gene that we found to
be associated with cardiomyopathy with p < 1 × 10−6. We closely examined this 48.3-Kb region
(chr2: 152758611-152806958) using the Encyclopedia of DNA Elements (ENCODE) resource [46].
Interestingly, this region is enriched with histone modification H3k27ac, indicating the presence
of active regulatory elements, especially enhancers and various transcription factor binding sites
(Supplementary Figure S9). This is consistent with the presence of DNA-sensitive loci in this region
(Supplementary Figure S9). It is also interesting that there is a predicted non-coding Mir-584 gene in
this region located near a histone modification H3k27ac peak. Mir-584 is down-regulated in blood cells
in coronary artery disease [47] and is involved in the etiology of hypertension [48]. It is tempting to
speculate that the genetic polymorphisms in this region may affect the activities of regulatory elements,
either enhancers or transcription factor binding or non-coding microRNA, to regulate gene expression
or splicing of CACNB4 transcripts. There are at least four transcript products of CACNB4 genes due to
alternative splicing. We did not find direct expression quantitative trait locus (eQTL) evidence in the
Genotype-Tissue Expression (GTEx) [49] database for these eight tag genetic variants at the CACNB4
locus, nor with an additional six genetic variants in LD with them (r2 > 0.2). All 14 of these SNPs
are intronic genetic variants within CACNB4. Further studies will be needed to delineate the exact
mechanisms on how the observed genetic variants regulate cardiomyocyte function.
To evaluate whether our single-variant level correlation analysis results would provide
mechanistic insights into the etiology of IDC in African Americans, we examined the enriched
pathways in the top GWAS signals. Cardiomyopathy pathways, including those described for IDC,
HCM, and arrhythmogenic right ventricular cardiomyopathy (ARVC), and cardiac hypertrophy
signals are significantly overrepresented (Table 2 and Supplementary Table S4). At the cellular level,
the enriched pathways are indeed recognized to play roles in cardiomyopathy pathogenesis, such as
cAMP-related signals [50] and gap junction signals [51]. Consistent with our novel finding on calcium
channel subunit CACNB4 loci, intracellular calcium-related signals are also over-represented. Of note,
among the top 1000 genes are six that are known to harbor previously identified mutations associated
with rare familial HCM/IDC (GPD1L, MYH6, MYH7, PSEN2, GATAD1, and SGCD). Specifically, MYH7
and SGCD genes have mutations reported in IDC. These six genes are mainly involved in cardiac
muscle contraction function.
Neuronal signals were also significantly enriched in our top GWAS results (Table 2 and
Supplementary Table S4). Considering the cardiac muscle function is under direct control of
neuromuscular junction, this is not surprising. However, known cardiomyopathy mutations do
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not include any neuronal genes. Our finding may direct future mechanistic studies of cardiomyopathy
in new avenues, including pathways not yet implicated in IDC pathogenesis. We also replicated in this
African American sample an association with one (of four) SNPs previously associated with IDC in
European Caucasians, located in the intronic region of HSPB7.
There are several limitations to our study. The major limitation is that there are no other large
collections of African American IDC cases available for replication of the rs150793926 association,
at least none of which we are aware. The best variant rs150793926 in CACNB4, with genome-wide
significance, and the other seven variants in this locus with p < 1 × 10−6 were not present in earlier
GWAS data of IDC in European Caucasians.
In summary, our study suggests that, in addition to rare exonic mutations, common genetic
polymorphisms can also explain a significant portion of the etiology of IDC. Our results suggest that
IDC is a complex trait, likely involving multiple genetic variants, as well as environmental/comorbid
condition interactions. As such, the CACNB4 variant we identified may represent one of multiple
predisposing genetic variants in African Americans. The distinct differences in clinical characteristics
of IDC between African Americans and European Caucasians strongly support the inclusion of African
American subjects in genetic studies of this disorder and more generally the importance of examining
diverse populations to define racial differences in risk and prognoses phenotypes in IDC and other
forms of chronic heart failure. We would also like to emphasize that our GWAS findings are exploratory,
and a next step would be to replicate our findings in an independent cohort of African Americans.
Currently, the Precision Medicine Study of Dilated Cardiomyopathy (funded by NIH in 2015) aims to
phenotype and perform exome-sequencing on 1300 people with dilated cardiomyopathy (including
600 African American) and their 5200 family members from 11 sites across the United States [10].
Combining results and or performing joint analyses of all available African American data sets will
be an important future direction. In addition, large cohorts with genomics data such as the USA
Department of Veterans Affairs' Million Veteran Program targeting for 1 million participants [52]
may be useful for this purpose too. Given the differences in cardiomyopathy rates between African
Americans and European Caucasians, analytic approaches such as admixture mapping might also be
helpful. Although there is biologic plausibility supporting our findings, further in vitro, human tissue,
or genetically modified mouse studies of the CACNB4 intronic region will be required to establish the
mechanism by which the variation causes predisposition to IDC.
Supplementary Materials: The following are available online at www.mdpi.com/2075-4426/8/1/11/s1, Table S1:
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ancestry comparison between cases and controls; Figure S3: The genetic variance accounted for by each principal
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each chromosome; Figure S7: Quantile–quantile plots of genome-wide association p values; Figure S8: Regional
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